ClinicalTrials.gg
Not yet recruitingNCT07341828Updated Jan 15, 2026

A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy

A Phase 1 interventional study of CD20/BCMA-directed CAR-T cells in Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD) and Autoimmune Encephalitis, sponsored by Huashan Hospital. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Huashan Hospital · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with central nervous system autoimmune diseases refractory to standard therapy

02

Conditions studied

  • Multiple Sclerosis (MS)
  • Neuromyelitis Optica Spectrum Disorders (NMOSD)
  • Autoimmune Encephalitis
  • Stiff Person Syndrome

Keywords

  • CD20/BCMA-directed CAR-T cells
03

In context

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

This study's planned enrollment of 15 is below the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.

Browse Multiple Sclerosis studies →

Lead sponsor

Huashan Hospital is the lead sponsor of 248 studies on the registry; 105 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 70 years old at the time of signing the Form (ICF).
  • Diagnosed as Multiple Sclerosis (MS)/Neuromyelitis Optica Spectrum Disorders (NMOSD)/ Encephalitis(AiE)/Stiff Person Spectrum Disorder(SPSD) according to recognized diagnostic criteria for at least 6 months.
  • Prior treatment failure with standard therapy.
  • Adequate bone marrow, coagulation, cardiopulmonary, liver and renal function.

Exclusion criteria

Exclusion Criteria:

  • Virus (HBV), Virus (HCV), (HIV), Treponema Pallidum (TP) positive, Cytomegalovirus (CMV) DNA positive, Epstein-Barr Virus (EBV) DNA positive.
  • Uncontrolled active infection.
  • injection within 4 weeks prior to signing the ICF.
  • Major organ transplantation history or bone marrow/hematopoietic stem cell transplantation history.
  • Severe cardiovascular diseases within the past 6 months prior to screening.
  • A history of ≥ Grade 2 bleeding within 4 weeks prior to screening, or requiring long-term anticoagulants treatment.
  • Inadequate washing time for previous treatment.
  • Previously treated with CAR-T cell products or genetically modified T cell therapies.
  • Pregnant or lactating women.
  • Severe central nervous system diseases or pathological changes.
  • history within 5 years prior to signing the ICF.
  • Any to lumbar puncture.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    C-CAR168

    Autologous C-CAR168 administered by intravenous (IV) infusion

    Biological: CD20/BCMA-directed CAR-T cells

Interventions

  • BiologicalCD20/BCMA-directed CAR-T cells

    Autologous 2nd generation CD20/BCMA-directed CAR-T cells, single infusion intravenously

    Also known as: C-CAR168

06

What researchers measure

Primary outcomes

  1. Incidence and severity of Adverse Events [Safety and Tolerability]

    Incidence and severity of adverse events (AE) and serious adverse events (SAE) within three months following infusion

    Time frame: Throughout the first 3 months follow up period completion

  2. The subsequent recommended dose of C-CAR168 in patients with central nervous system autoimmune diseases refractory to standard therapy

    Based on the assessment of overall safety profile

    Time frame: Throughout the first 24 months follow up period completion

Secondary outcomes

  1. Incidence and severity of adverse events (AE)

    Incidence and severity of adverse events (AE) and serious adverse events (SAE) during the study

    Time frame: Throughout the first 24 months follow up period completion

  2. MS: No Evidence of Disease Activity-3 (NEDA-3)

    Proportion of participants achieving NEDA-3 at 6 months post-infusion and during the study period

    Time frame: Throughout the first 24 months follow up period completion

  3. MS and NMOSD: Expanded Disability Status Scale (EDSS)

    Change from baseline in EDSS at 6 months and 24 months post-infusion. EDSS and its associated functional system (FS) score provide a system for quantifying disability and monitoring changes in the level of disability over time. EDSS consists of 7 FS (visual FS, brainstem FS, pyramidal FS, cerebellar FS, sensory FS, bowel and bladder FS, and cerebral FS) which are used to derive EDSS score ranging from 0 (normal neurological exam) to 10 (death).

    Time frame: Throughout the first 24 months follow up period completion

  4. MS and NMOSD: MRI

    Number of T1 gadolinium-enhancing lesions and new or enlarging T2 lesions, as well as their change from baseline, at 6 months and 24 months post-infusion. Change from baseline in total T2 lesion volume, gray matter volume (GMV), white matter volume (WMV), and brain volume (BV), as well as annualized-brain volume loss (a-BVL), at 6 months and 24 months post-infusion

    Time frame: Throughout the first 24 months follow up period completion

  5. Autoimmune Encephalitis (AiE): Clinical Assessment Scale in Autoimmune Encephalitis (CASE)

    Change from baseline in CASE at 6 months and 24 months post-infusion. The Clinical Assessment Scale in Autoimmune Encephalitis (CASE) has a score range from 0 to 27, and higher scores indicate a worse clinical outcome.

    Time frame: Throughout the first 24 months follow up period completion

  6. MS, NMOSD and AiE: Annualized Relapse Rate (ARR)

    ARR at 6 months and 24 months post-infusion

    Time frame: Throughout the first 24 months follow up period completion

  7. Stiff-Person Syndrome (SPS): Distribution of Stiffness Index (DSI)

    Change from baseline in DSI at 6 months and 24 months post-infusion. Distribution of Stiffness Index (DSI) is a validated indicator or stiffness. Scores range from 0 to 6 and reflect the extent of stiffness. Higher scores indicate a worse outcome.

    Time frame: Throughout the first 24 months follow up period completion

  8. SPS: Heightened Sensitivity Score (HSS)

    Change from baseline in HSS at 6 months and 24 months post-infusion. Heightened Sensitivity Score (HSS) measures changes in the frequency of spasms. Scores range from 0 to 7. Higher scores indicate a worse outcome.

    Time frame: Throughout the first 24 months follow up period completion

  9. Pharmacokinetics (PK): Maximal plasma concentration (Cmax)

    Cmax of C-CAR168 in peripheral blood

    Time frame: Throughout the first 24 months follow up period completion

  10. PK: Time to reach the maximal plasma concentration (Tmax)

    Tmax of C-CAR168 in peripheral blood

    Time frame: Throughout the first 24 months follow up period completion

  11. PK: Duration in peripheral blood (Tlast)

    Tlast of C-CAR168 in peripheral blood

    Time frame: Throughout the first 24 months follow up period completion

  12. PK: Area under curve (AUC)

    AUC of C-CAR168 in peripheral blood

    Time frame: Throughout the first 24 months follow up period completion

  13. Pharmacodynamics (PD): Depletion of peripheral blood B cells, plasma cells, and CD20dim T cells

    Time frame: Throughout the first 24 months follow up period completion

  14. PD: Decline of serum immunoglobulin

    Time frame: Throughout the first 24 months follow up period completion

Other outcomes

  1. Serum cytokines changes

    Detection of serum cytokines changes over time by flow cytometry

    Time frame: Throughout the first 24 months follow up period completion

  2. Soluble BCMA changes in peripheral blood

    Detection of soluble BCMA changes in peripheral blood by Enzyme Linked ImmunoSorbent Assay (ELISA)

    Time frame: Throughout the first 24 months follow up period completion

  3. Changes in CSF CAR DNA copy number and CAR-T cells

    Detection of changes in CSF CAR DNA copy number and CAR-T cells by quantitative polymerase chain reaction (qPCR) and flow cytometry

    Time frame: Throughout the first 24 months follow up period completion

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Jun 2027, 16 months later.

Of 53 non-industry phase 1 interventional studies under Multiple Sclerosis, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's planned 16 months is below that.

Counting every sponsor, half of 92 studies reached it within 30 months; a quarter within 9 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2026
First posted
Jan 14, 2026
StartEst.
Feb 2026
Primary completionEst.
Jun 2027
CompletionEst.
Feb 2029
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07341828
Lead sponsor
Huashan Hospital
Responsible party
Xiangjun Chen (Professor of Neurology, Huashan Hospital) — Principal investigator
First posted
Jan 14, 2026
Start date
Feb 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Feb 2029 (estimated)
Last update
Jan 15, 2026

Study contacts

Xiangjun Chen
Contact
xiangjchen@fudan.edu.cn
+86 21 52888159

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion